Breaking News, Financial News

Abbvie FY Revenues up 23%

Revenues from the neuroscience portfolio up 19% and global Botox Therapeutic revenues were up 18% in the quarter.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Abbvie 4Q Revenues: $14.9 billion (+7%) 4Q Earnings: $4.0 billion (earnings were $36 million 4Q21) FY Revenues: $56.2 billion (+23%) FY Earnings: $3.4 billion (-10%) Comments: Global Humira revenues were $5.3 billion in the quarter, an increase of 3.5%. Global Skyrizi revenues were $895 million and Rinvoq revenues were $517 million. Global revenues from the hematologic oncology portfolio were $1.9 billion, an increase of 4.6% in the quarter. Global Imbruvica revenues were $1.385 billion, a ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters